Dr Reddy Laboratories Ltd was incorporated in India as a Private Limited Company on February 24, 1984. The Company converted to a Public Limited Company on December 6, 1985. The Company together with its subsidiaries is an India-based pharmaceutical company engaged in manufacturing of pharmaceutical products. The Company operates through three segments; Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. The Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients ("APIs"), Custom Pharmaceutical Services ("CPS"), generics, biosimilars, differentiated formulations and New Chemical Entities ("NCEs"). The Global Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company's biologics business. The Pharmaceutical Services and Active Ingredients segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The Company's differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment also includes the Company's specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The Company's products includes; Zoledronic acid, Azacitidine, Moxifloxacin, Decitabine, Donepezil 23 mg, and Sumatriptan Auto Injector. The Company's competitors include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited. Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Limited, Nycomed International Management GmbH and Zentiva N.V. The Company's manufacturing and marketing of drugs, drug products and cosmetics is governed by many statutes, regulations and guidelines, including; Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945; Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954; Medicinal and Toilet Preparations (Excise Duties) Act, 1955; and National Pharmaceuticals Pricing Policy, 2012.